Aprea Therapeutics Inc Myeloid Malignancy Regulatory Update Call Transcript
Good morning, ladies and gentlemen, and welcome to the Aprea Therapeutics Update Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Greg Korbel.
Hello, everyone. This is Greg Korbel, Chief Business Officer of Aprea Therapeutics, and I thank you for joining our conference call this morning.
Before we move into the main topic for today's call, I will take this moment to tell you that today's discussion and answers to questions will contain forward-looking statements. As such, please refer to our press release and periodic filings with the SEC for a description of the risks and uncertainties associated with our business. These filings may be accessed through the Investor and Media section of our website or found on sec.gov.
Today's call will include a question-and-answer session following comments from Aprea's management team. We kindly ask that you hold your questions
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |